TMCnet News
Research and Markets: MediPoint: Companion Diagnostic Tests in Oncology Report 2014 - US Analysis and Market ForecastsDUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/9g79jd/medipoint) has announced the addition of the "MediPoint: Companion Diagnostic Tests in Oncology - US Analysis and Market Forecasts" report to their offering. A companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows the safe application of a therapy. In-vitro Companion Diagnostic tests measure the expression or presence of a specific biomarker that is linked to a disease condition or therapy. This report provides an analysis of the companion diagnostic market for four major cancers in the US, the 5EU (France, Germany, Italy, Spain, and UK), Brazil, and the some of the Asia-Pacific (APAC) regions (Japan, China, and India), and identifies the unmet needs in this companion diagnostics market. This report analyses companion diagnostic tests used in breast, colorectal, melanoma and non-small cell lung cancer. This report also discusses physician attitudes towards current companion diagnostic tests, and the future of companion diagnostic tests. This report focuses on the major test kits that are supplied to pathology laboratories. The major feature of the companion diagnostic testing market is the current domination of tests for mutations important in the prognosis and diagnosis of non-small cell lung cancer (NSCLC), with the two market leaders being Roche and Qiagen. According to Our forecast, in 2014, NSCLC companion diagnostic tests account for 67% of the US market by value. While more human epidermal growth factor receptor 2 (HER2) tests are carried out, because the NSCLC tests have been principally more expensive molecular tests rather than the cheaper immunohistochemistry (IHC) test that typifies HER2 testing, the value of the NSCLC market is considerably higher. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Industry Overview
4 Competitive Assessment
5 Unmet Needs
6 Pipeline Products
7 Clinical Trials to Watch
8 Current and Future Players
9 Market Outlooks
10 Appendix Companies Mentioned
For more information visit http://www.researchandmarkets.com/research/9g79jd/medipoint
|